Harnessing the hypoxia-inducible factor in cancer and ischemic disease

Biochemical Pharmacology

Volumn 73, Issue 3, 2007, Pages 450-457

  Brahimi Horn, M Christiane ^a   Pouysségur, Jacques ^a  

^a UNIVERSITÉ CÔTE D'AZUR   (France)

Author keywords

Angiogenesis; Arrest defective protein; Cancer; Factor inhibiting HIF; Hypoxia inducible factor; Oxygen sensor; Prolyl hydroxylase domain; Tumour invasion and metabolism

Indexed keywords

ANGIOGENESIS INHIBITOR; ASPARAGINYL HYDROXYLASE; CYTOTOXIC AGENT; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 3; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; RAF PROTEIN; RAS PROTEIN;

ARTICLE; CANCER; CELL INVASION; CELL PH; CELL PROLIFERATION; CONTROLLED STUDY; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; ISCHEMIA; MICROENVIRONMENT; OXYGEN CONSUMPTION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REPRESSOR GENE; SIGNAL TRANSDUCTION; TISSUE OXYGENATION; TRANSCRIPTION REGULATION; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL SURVIVAL; GENE EXPRESSION REGULATION; GLYCOLYSIS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; ISCHEMIA; NEOPLASM METASTASIS; NEOPLASMS; OXIDATIVE PHOSPHORYLATION; PROTEIN BIOSYNTHESIS; SIGNAL TRANSDUCTION; TRANS-ACTIVATION (GENETICS);

EID: 33845630758     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2006.10.013     Document Type: Article

References (53)

1. Schofield C.J., and Ratcliffe P.J. Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol 5 (2004) 343-354
2. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3 (2003) 721-732
3. Brahimi-Horn C., Mazure N., and Pouyssegur J. Signalling via the hypoxia-inducible factor-1alpha requires multiple posttranslational modifications. Cell Signal 17 (2005) 1-9
4. Kaelin Jr. W.G. The von Hippel-Lindau gene, kidney cancer, and oxygen sensing. J Am Soc Nephrol 14 (2003) 2703-2711
5. Schofield C.J., and Ratcliffe P.J. Signalling hypoxia by HIF hydroxylases. Biochem Biophys Res Commun 338 (2005) 617-626
6. Nakayama K., Frew I.J., Hagensen M., Skals M., Habelhah H., Bhoumik A., et al. Siah2 regulates stability of prolyl-hydroxylases, controls HIF1alpha abundance, and modulates physiological responses to hypoxia. Cell 117 (2004) 941-952
7. Gottlieb E., and Tomlinson I. Mitochondrial tumor suppressors: Genetic and Biochemical update. Nat Rev Cancer 5 (2005) 857-866
8. Bilton R., Mazure N., Trottier E., Hattab M., Dery M.A., Richard D.E., et al. Arrest-defective-1 protein, an acetyltransferase, does not alter stability of hypoxia-inducible factor (HIF)-1alpha and is not induced by hypoxia or HIF. J Biol Chem 280 (2005) 31132-31140
9. Bilton R., Trottier E., Pouysségur J., and Brahimi-Horn M.C. ARDent about acetylation and deacetylation in hypoxia signalling. Trends Cell Biol 16 (2006) 616-621
10. Pouysségur J., and Mechta-Grigoriou F. Redox regulation of the hypoxia-inducible factor. Biol Chem 387 (2006) 1337-1346
11. Manalo D.J., Rowan A., Lavoie T., Natarajan L., Kelly B.D., Ye S.Q., et al. Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood 105 (2005) 659-669
12. Sang N., Stiehl D.P., Bohensky J., Leshchinsky I., Srinivas V., and Caro J. MAPK signaling up-regulates the activity of hypoxia-inducible factors by its effects on p300. J Biol Chem 278 (2003) 14013-14019
13. Brahimi-Horn M.C., and Pouyssegur J. The hypoxia-inducible factor and tumor progression along the angiogenic pathway. Int Rev Cytol 242 (2005) 157-213
14. Maynard M.A., Qi H., Chung J., Lee E.H., Kondo Y., Hara S., et al. Multiple splice variants of the human HIF-3 alpha locus are targets of the von Hippel-Lindau E3 ubiquitin ligase complex. J Biol Chem 278 (2003) 11032-11040
15. Makino Y., Cao R., Svensson K., Bertilsson G., Asman M., Tanaka H., et al. Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression. Nature 414 (2001) 550-554
16. Gruber M., and Simon M.C. Hypoxia-inducible factors, hypoxia, and tumor angiogenesis. Curr Opin Hematol 13 (2006) 169-174
17. Wykoff C.C., Beasley N.J., Watson P.H., Turner K.J., Pastorek J., Sibtain A., et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 60 (2000) 7075-7083
18. Aprelikova O., Chandramouli G.V., Wood M., Vasselli J.R., Riss J., Maranchie J.K., et al. Regulation of HIF prolyl hydroxylases by hypoxia-inducible factors. J Cell Biochem 92 (2004) 491-501
19. Dayan F., Roux D., Brahimi-Horn M.C., Pouyssegur J., and Mazure N.M. The oxygen sensor factor-inhibiting hypoxia-inducible factor-1 controls expression of distinct genes through the bifunctional transcriptional character of hypoxia-inducible factor-1alpha. Cancer Res 66 (2006) 3688-3698
20. Muratani M., and Tansey W.P. How the ubiquitin-proteasome system controls transcription. Nat Rev Mol Cell Biol 4 (2003) 192-201
21. Koivunen P., Hirsila M., Gunzler V., Kivirikko K.I., and Myllyharju J. Catalytic properties of the asparaginyl hydroxylase (FIH) in the oxygen sensing pathway are distinct from those of its prolyl 4-hydroxylases. J Biol Chem 279 (2004) 9899-9904
22. Stolze I.P., Tian Y.M., Appelhoff R.J., Turley H., Wykoff C.C., Gleadle J.M., et al. Genetic analysis of the role of the asparaginyl hydroxylase factor inhibiting hypoxia-inducible factor (HIF) in regulating HIF transcriptional target genes. J Biol Chem 279 (2004) 42719-42725
23. Pouyssegur J., Dayan F., and Mazure N.M. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 441 (2006) 437-443
24. Gatenby R.A., and Gillies R.J. Why do cancers have high aerobic glycolysis?. Nat Rev Cancer 4 (2004) 891-899
25. Matoba S., Kang J.G., Patino W.D., Wragg A., Boehm M., Gavrilova O., et al. p53 regulates mitochondrial respiration. Science 312 (2006) 1650-1653
26. Fantin V.R., St-Pierre J., and Leder P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 9 (2006) 425-434
27. Kim J.W., Tchernyshyov I., Semenza G.L., and Dang C.V. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab 3 (2006) 177-185
28. Papandreou I., Cairns R.A., Fontana L., Lim A.L., and Denko N.C. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab 3 (2006) 187-197
29. Counillon L., and Pouyssegur J. The expanding family of eucaryotic Na(+)/H(+) exchangers. J Biol Chem 275 (2000) 1-4
30. Potter C., and Harris A.L. Hypoxia inducible carbonic anhydrase IX, marker of tumour hypoxia, survival pathway and therapy target. Cell Cycle 3 (2004) 164-167
31. Pouyssegur J, Franchi A, Pages G, pHi, aerobic glycolysis and vascular endothelial growth factor in tumour growth. In: Novartis Found Symp2001: John Wiley & Sons, Ltd. p. 186-96.
32. Shimoda L.A., Fallon M., Pisarcik S., Wang J., and Semenza G.L. HIF-1 regulates hypoxic induction of NHE1 expression and alkalinization of intracellular pH in pulmonary arterial myocytes. Am J Physiol Lung Cell Mol Physiol (2006)
33. Ullah M.S., Davies A.J., and Halestrap A.P. The plasma membrane lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through a HIF-1alpha dependent mechansm. J Biol Chem 281 (2006) 9030-9037
34. Cardone R.A., Casavola V., and Reshkin S.J. The role of disturbed pH dynamics and the Na+/H+ exchanger in metastasis. Nat Rev Cancer 5 (2005) 786-795
35. Guertin D.A., and Sabatini D.M. An expanding role for mTOR in cancer. Trends Mol Med 11 (2005) 353-361
36. Brugarolas J., Lei K., Hurley R.L., Manning B.D., Reiling J.H., Hafen E., et al. Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev 18 (2004) 2893-2904
37. Brugarolas J.B., Vazquez F., Reddy A., Sellers W.R., and Kaelin Jr. W.G. TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell 4 (2003) 147-158
38. Pages G., and Pouyssegur J. Transcriptional regulation of the vascular endothelial growth factor gene-a concert of activating factors. Cardiovasc Res 65 (2005) 564-573
39. Kondo Y., Kanzawa T., Sawaya R., and Kondo S. The role of autophagy in cancer development and response to therapy. Nat Rev Cancer 5 (2005) 726-734
40. Greijer A.E., and van der Wall E. The role of hypoxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis. J Clin Pathol 57 (2004) 1009-1014
41. Walenta S., and Mueller-Klieser W.F. Lactate: mirror and motor of tumor malignancy. Semin Radiat Oncol 14 (2004) 267-274
42. Esteban M.A., Tran M.G., Harten S.K., Hill P., Castellanos M.C., Chandra A., et al. Regulation of E-cadherin expression by VHL and hypoxia-inducible factor. Cancer Res 66 (2006) 3567-3575
43. Ferrara N., and Kerbel R.S. Angiogenesis as a therapeutic target. Nature 438 (2005) 967-974
44. Melillo G. Inhibiting hypoxia-inducible factor 1 for cancer therapy. Mol Cancer Res 4 (2006) 601-605
45. Peyssonaux C., and Johnson R.S. An unexpected role for hypoxic response: oxygenation and inflammation. Cell Cycle 3 (2004) 168-171
46. Pennacchietti S., Michieli P., Galluzzo M., Mazzone M., Giordano S., and Comoglio P.M. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 3 (2003) 347-361
47. Tam B.Y., Wei K., Rudge J.S., Hoffman J., Holash J., Park S.K., et al. VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis. Nat Med 12 (2006) 793-800
48. Giaccia A., Siim B.G., and Johnson R.S. HIF-1 as a target for drug development. Nat Rev Drug Discov 2 (2003) 803-811
49. Hewitson K.S., and Schofield C.J. The HIF pathway as a therapeutic target. Drug Discov Today 9 (2004) 704-711
50. Paul S.A., Simons J.W., and Mabjeesh N.J. HIF at the crossroads between ischemia and carcinogenesis. J Cell Physiol 200 (2004) 20-30
51. Rapisarda A., Uranchimeg B., Sordet O., Pommier Y., Shoemaker R.H., and Melillo G. Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. Cancer Res 64 (2004) 1475-1482
52. Shaked Y., Ciarrocchi A., Franco M., Lee C.R., Man S., Cheung A.M., et al. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 313 (2006) 1785-1787
53. Sengupta S., Eavarone D., Capila I., Zhao G., Watson N., Kiziltepe T., et al. Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature 436 (2005) 568-572